In a filing with the US Securities and Exchange Commission (SEC), Boston-based rare disease specialist Imara (Nasdaq: IMRA) has disclosed savage job cuts as part of an extensive restructuring.
Only six full-time employees will remain at the firm following the plan, which comes after disappointing results from interim analyses of the Phase IIb ARDENT study.
The company was testing tovinontrine in sickle cell disease and beta thalassemia, as well as in a type of heart failure, but opted to axe the program following the negative readout.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze